Optimal use of targeted agents for advanced gastrointestinal stromal tumours.
Imatinib is the recommended 1st-line treatment for a KIT-positive unresectable and/or metastatic gastrointestinal stromal tumour (GIST). However, some patients experience intolerance to imatinib and most patients will eventually experience disease progression while on imatinib treatment. Sunitinib is approved for treatment of a GIST after disease progression on, or intolerance to, imatinib therapy. Progression may occur early or later on, in treatment and is determined by factors including initial GIST genotype and mutational status. GISTs with KIT exon 11 mutations appear to be sensitive to standard dose imatinib, and patients with GISTs exhibiting KIT exon 9 mutations whose disease has progressed on imatinib 400 mg/day have been shown to respond to imatinib 800 mg/day, albeit with a higher incidence of adverse events. Sunitinib has shown clinical benefit in all major GIST mutational subtypes, particularly in patients with wild-type or KIT exon 9 genotype and against GISTs with secondary KIT exon 13 or 14 mutations. The choice between higher-dose imatinib and sunitinib after progression on standard dose imatinib is unclear, and apart from the GIST primary resistance genotype and mutational status, individual patient factors such as tumour characteristics, drug pharmacokinetics, and other clinical factors may affect response to treatment. Individualisation of therapy may help to maximise clinical benefit of therapy in these patients.
Reichardt
Peter
P
HELIOS Klinikum Bad Saarow, Bad Saarow, Germany. peter.reichardt@helios-kliniken.de
D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D001549:Benzamides; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004252:DNA Mutational Analysis; D019008:Drug Resistance, Neoplasm; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000627:therapeutic use / Q000633:toxicity; D009154:Mutation; D009367:Neoplasm Staging; D010879:Piperazines / Q000627:therapeutic use / Q000633:toxicity; D011743:Pyrimidines / Q000627:therapeutic use / Q000633:toxicity; D011758:Pyrroles / Q000627:therapeutic use / Q000633:toxicity; D000077210:Sunitinib; D015996:Survival Rate; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D007211:Indoles; D010879:Piperazines; D011743:Pyrimidines; D011758:Pyrroles; D000068877:Imatinib Mesylate; D000077210:Sunitinib
Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34
15451219
J Clin Oncol. 2003 Dec 1;21(23):4342-9
14645423
Cancer Chemother Pharmacol. 2005 Apr;55(4):379-386
15592836
Clin Exp Metastasis. 2003;20(8):757-66
14713109
J Clin Oncol. 2009 Jul 1;27(19):3141-7
19451435
Cancer Chemother Pharmacol. 2010 Jul;66(2):357-71
19967539
Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7
19164557
Blood. 2004 Nov 1;104(9):2940-2
15251980
Recent Pat Anticancer Drug Discov. 2008 Jun;3(2):88-99
18537751
Eur J Cancer. 2009 Jul;45(11):1959-68
19282169
J Clin Endocrinol Metab. 2006 Oct;91(10):4070-6
16849418
Br J Cancer. 2008 Feb 26;98(4):684-8
18253129
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Oct 15;874(1-2):84-8
18823825
J Clin Oncol. 2009 Jan 20;27(3):439-45
19064982
J Clin Oncol. 2008 Nov 20;26(33):5352-9
18955458
Mol Cancer Ther. 2003 May;2(5):471-8
12748309
Eur J Cancer. 2003 Sep;39(14):2006-11
12957454
J Gastrointest Surg. 2009 Sep;13(9):1583-92
19291337
Eur J Cancer. 2006 May;42(8):1093-103
16624552
Lancet. 2006 Oct 14;368(9544):1329-38
17046465
Clin Cancer Res. 2003 Feb;9(2):625-32
12576428
Expert Opin Investig Drugs. 2009 Apr;18(4):457-68
19335275
Ther Clin Risk Manag. 2008 Feb;4(1):149-62
18728705
J Clin Oncol. 2005 Aug 10;23(23):5357-64
15928335
Invest New Drugs. 1992 Nov;10(4):239-53
1487397
Int J Cancer. 2005 Nov 1;117(2):289-93
15900576
J Clin Oncol. 2006 Oct 10;24(29):4764-74
16954519
Eur J Cancer. 2005 Dec;41(18):2868-72
16293410
J Clin Oncol. 2007 May 1;25(13):1760-4
17470866
Eur J Cancer. 2005 Aug;41(12):1751-7
16098458
Oncologist. 2007 Jun;12(6):719-26
17602061
J Clin Oncol. 2008 Feb 1;26(4):620-5
18235121
J Clin Oncol. 2007 May 1;25(13):1753-9
17470865
Cancer. 2005 Feb 15;103(4):821-9
15648083
Eur J Cancer. 2009 Sep;45(13):2293-7
19467857
Curr Oncol Rep. 2008 Jul;10(4):344-9
18778561
Blood. 2003 May 1;101(9):3597-605
12531805
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jul 15;877(22):1982-96
19505856
J Clin Oncol. 2005 Aug 20;23(24):5795-804
16110036
Lancet. 2009 Mar 28;373(9669):1097-104
19303137
Clin Cancer Res. 2003 Jan;9(1):327-37
12538485
Clin Cancer Res. 2005 Jun 1;11(11):4182-90
15930355
Hematol Oncol Clin North Am. 2009 Feb;23(1):139-50, x
19248977
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
J Clin Oncol. 2008 Feb 1;26(4):626-32
18235122
Ann Oncol. 2009 May;20 Suppl 4:64-7
19454466
J Nucl Med. 2004 Mar;45(3):357-65
15001674
N Engl J Med. 2002 Aug 15;347(7):472-80
12181401
J Clin Oncol. 2008 Feb 1;26(4):570-6
18235116